candesartan and Cardiomegaly
candesartan has been researched along with Cardiomegaly in 30 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" Many lines of evidence have suggested that angiotensin II (Ang II) plays a vital role in cardiac hypertrophy, and it has been reported that secretion of Ang II from cultured cardiac myocytes was induced by mechanical stretch." | 7.69 | Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. ( Hiroi, Y; Komuro, I; Kudoh, S; Mizuno, T; Shiojima, I; Takano, H; Tobe, K; Ueki, K; Yamazaki, T; Zou, Y, 1995) |
"The angiotensin II (AngII) type 1 (AT1) receptor is a seven transmembrane-spanning G-protein-coupled receptor, and the activation of AT1 receptor plays an important role in the development of load-induced cardiac hypertrophy." | 4.84 | A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. ( Akazawa, H; Komuro, I; Qin, Y; Yasuda, N; Zou, Y, 2008) |
" After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
" Here we compared the effects of five commonly used ARBs (Candesartan, Olmesartan, Losartan, Telmisartan and Valsartan) on pressure overload-induced cardiac hypertrophy in mice model." | 3.76 | Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. ( Ge, J; Gong, H; Komuro, I; Li, L; Lin, L; Wu, J; Zhou, N; Zou, Y, 2010) |
" Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
"The angiotensin II type 1 (AT1) receptor has a crucial role in load-induced cardiac hypertrophy." | 3.72 | Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. ( Akazawa, H; Fujita, T; Fukamizu, A; Iiri, T; Iwanaga, K; Kihara, M; Komuro, I; Kudoh, S; Makita, N; Minamino, T; Nagai, T; Qin, Y; Sano, M; Takano, H; Tamura, K; Toko, H; Umemura, S; Zhu, W; Zou, Y, 2004) |
"The possible role of calcineurin in the attenuation of cardiac hypertrophy and fibrosis by blockade of the angiotensin II type 1 (AT1) receptor was investigated in Dahl salt-sensitive (DS) rats." | 3.71 | AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. ( Ichihara, S; Iwase, M; Izawa, H; Nagasaka, T; Nagata, K; Nakashima, N; Obata, K; Odashima, M; Somura, F; Yamada, Y; Yokota, M, 2002) |
" Chronic treatment with enalapril or candesartan inhibited the development of hypertension and cardiac hypertrophy equally in SHR." | 3.71 | Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats. ( Harada, S; Hatta, T; Kawa, T; Kido, H; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Oguni, A; Sasaki, S; Takeda, K, 2002) |
" Many lines of evidence have suggested that angiotensin II (Ang II) plays a vital role in cardiac hypertrophy, and it has been reported that secretion of Ang II from cultured cardiac myocytes was induced by mechanical stretch." | 3.69 | Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. ( Hiroi, Y; Komuro, I; Kudoh, S; Mizuno, T; Shiojima, I; Takano, H; Tobe, K; Ueki, K; Yamazaki, T; Zou, Y, 1995) |
"Candesartan-pretreated SHHF (5 mg/kg/day candesartan; weeks 4-8) received during adulthood (20-28 weeks of age) either candesartan at a dose of 1." | 1.36 | Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment. ( Baumann, M; Heemann, U; Lutz, J; Roos, M; Sollinger, D, 2010) |
"Chronic isoproterenol (ISO)-induced cardiac hypertrophy was inhibited in wild-type mice and AT1aR(-/-) mice treated with the ARB Candesartan (CV11974)." | 1.36 | Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors. ( Kimura, S; Matsuyoshi, H; Murao, K; Obata, K; Takaki, M; Yu, X; Zhang, GX, 2010) |
"Pressure overload induced cardiac hypertrophy in angiotensinogen null mice as well as in wild-type mice, which was significantly inhibited by candesartan." | 1.33 | A novel mechanism of mechanical stress-induced hypertrophy. ( Akazawa, H; Komuro, I; Zou, Y, 2006) |
"Candesartan treatment decreased cardiac PAI-1 expression only in the dark in WKY rats but throughout the day in SHR." | 1.32 | Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. ( Fujioka, Y; Iwasaki, T; Kawasaki, D; Masai, M; Morimoto, S; Naito, Y; Ohyanagi, M; Okumura, T; Sakoda, T; Tsujino, T, 2003) |
"Also, low-dose perindopril prevented cardiac hypertrophy and fibrosis." | 1.32 | Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. ( Horikoshi, K; Izumi, T; Mochizuki, S; Nagai, M; Seki, S; Taniguchi, I; Taniguchi, M, 2004) |
Research
Studies (30)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (20.00) | 18.2507 |
2000's | 17 (56.67) | 29.6817 |
2010's | 7 (23.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ohkura, SI | 1 |
Usui, S | 1 |
Takashima, SI | 1 |
Takuwa, N | 1 |
Yoshioka, K | 1 |
Okamoto, Y | 1 |
Inagaki, Y | 1 |
Sugimoto, N | 1 |
Kitano, T | 1 |
Takamura, M | 1 |
Wada, T | 1 |
Kaneko, S | 1 |
Takuwa, Y | 1 |
Moinuddin, G | 1 |
Inamdar, MN | 1 |
Kulkarni, KS | 1 |
Kulkarni, C | 1 |
Suzuki, H | 1 |
Katanasaka, Y | 1 |
Sunagawa, Y | 1 |
Miyazaki, Y | 1 |
Funamoto, M | 1 |
Wada, H | 1 |
Hasegawa, K | 1 |
Morimoto, T | 1 |
Nakamura, K | 1 |
Koibuchi, N | 1 |
Nishimatsu, H | 1 |
Higashikuni, Y | 1 |
Hirata, Y | 2 |
Kugiyama, K | 1 |
Nagai, R | 2 |
Sata, M | 1 |
Takahara, A | 1 |
Nakamura, Y | 1 |
Wagatsuma, H | 1 |
Aritomi, S | 1 |
Nakayama, A | 1 |
Satoh, Y | 1 |
Akie, Y | 1 |
Sugiyama, A | 1 |
Baumann, M | 1 |
Sollinger, D | 1 |
Roos, M | 1 |
Lutz, J | 1 |
Heemann, U | 1 |
Ocaranza, MP | 1 |
Lavandero, S | 1 |
Jalil, JE | 1 |
Moya, J | 1 |
Pinto, M | 1 |
Novoa, U | 1 |
Apablaza, F | 1 |
Gonzalez, L | 1 |
Hernandez, C | 1 |
Varas, M | 1 |
Lopez, R | 1 |
Godoy, I | 1 |
Verdejo, H | 1 |
Chiong, M | 1 |
Zhang, GX | 1 |
Kimura, S | 1 |
Murao, K | 1 |
Yu, X | 1 |
Obata, K | 2 |
Matsuyoshi, H | 1 |
Takaki, M | 1 |
Li, L | 1 |
Zhou, N | 1 |
Gong, H | 1 |
Wu, J | 1 |
Lin, L | 1 |
Komuro, I | 8 |
Ge, J | 1 |
Zou, Y | 7 |
Shimizu, T | 1 |
Hirayama, H | 1 |
Hiramitsu, S | 1 |
Shimizu, K | 1 |
Yoshida, O | 1 |
Miao, CY | 1 |
Xie, HH | 1 |
Wang, JJ | 1 |
Su, DF | 1 |
Nagata, K | 1 |
Somura, F | 1 |
Odashima, M | 1 |
Izawa, H | 1 |
Ichihara, S | 1 |
Nagasaka, T | 1 |
Iwase, M | 1 |
Yamada, Y | 1 |
Nakashima, N | 1 |
Yokota, M | 1 |
Yayama, K | 1 |
Matsuoka, S | 1 |
Nagaoka, M | 1 |
Shimazu, E | 1 |
Takano, M | 1 |
Okamoto, H | 1 |
Naito, Y | 1 |
Tsujino, T | 1 |
Kawasaki, D | 1 |
Okumura, T | 1 |
Morimoto, S | 2 |
Masai, M | 1 |
Sakoda, T | 1 |
Fujioka, Y | 1 |
Ohyanagi, M | 1 |
Iwasaki, T | 1 |
Tanabe, A | 1 |
Naruse, M | 1 |
Hara, Y | 1 |
Sato, A | 1 |
Tsuchiya, K | 1 |
Nishikawa, T | 1 |
Imaki, T | 1 |
Takano, K | 1 |
Akazawa, H | 3 |
Qin, Y | 2 |
Sano, M | 2 |
Takano, H | 3 |
Minamino, T | 2 |
Makita, N | 1 |
Iwanaga, K | 1 |
Zhu, W | 1 |
Kudoh, S | 4 |
Toko, H | 1 |
Tamura, K | 1 |
Kihara, M | 1 |
Nagai, T | 1 |
Fukamizu, A | 1 |
Umemura, S | 1 |
Iiri, T | 1 |
Fujita, T | 1 |
Nagai, M | 1 |
Horikoshi, K | 1 |
Izumi, T | 1 |
Seki, S | 1 |
Taniguchi, M | 1 |
Taniguchi, I | 1 |
Mochizuki, S | 1 |
Iwashima, Y | 1 |
Okada, M | 1 |
Haneda, M | 1 |
Yoshida, T | 1 |
Okazaki, H | 1 |
Tsukamoto, O | 1 |
Kim, J | 1 |
Okada, K | 1 |
Myoishi, M | 1 |
Wakeno, M | 1 |
Takashima, S | 1 |
Mochizuki, N | 1 |
Kitakaze, M | 1 |
Takeda, Y | 1 |
Zhu, A | 1 |
Yoneda, T | 1 |
Usukura, M | 1 |
Takata, H | 1 |
Yamagishi, M | 1 |
Yasuda, N | 1 |
Nakamura, T | 1 |
Yamamoto, E | 1 |
Kataoka, K | 1 |
Yamashita, T | 1 |
Tokutomi, Y | 1 |
Dong, YF | 1 |
Matsuba, S | 1 |
Ogawa, H | 1 |
Kim-Mitsuyama, S | 1 |
Yamazaki, T | 3 |
Shiojima, I | 2 |
Mizuno, T | 2 |
Hiroi, Y | 2 |
Ueki, K | 1 |
Tobe, K | 1 |
Kanno, K | 1 |
Eguchi, S | 1 |
Kano, H | 1 |
Maemura, K | 1 |
Kurihara, H | 1 |
Aikawa, R | 2 |
Yazaki, Y | 2 |
Kodama, H | 1 |
Fukuda, K | 1 |
Pan, J | 1 |
Makino, S | 1 |
Takahashi, T | 1 |
Hori, S | 1 |
Ogawa, S | 1 |
Harada, M | 1 |
Saito, Y | 1 |
Nakagawa, O | 1 |
Miyamoto, Y | 1 |
Ishikawa, M | 1 |
Kuwahara, K | 1 |
Ogawa, E | 1 |
Nakayama, M | 1 |
Kamitani, S | 1 |
Hamanaka, I | 1 |
Kajiyama, N | 1 |
Masuda, I | 1 |
Itoh, H | 1 |
Tanaka, I | 1 |
Nakao, K | 1 |
Uozumi, H | 1 |
Miki, S | 1 |
Takeda, K | 1 |
Hatta, T | 1 |
Harada, S | 1 |
Kido, H | 1 |
Oguni, A | 1 |
Moriguchi, J | 1 |
Kawa, T | 1 |
Sasaki, S | 1 |
Nakagawa, M | 1 |
Reviews
1 review available for candesartan and Cardiomegaly
Article | Year |
---|---|
A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2008 |
Trials
1 trial available for candesartan and Cardiomegaly
Article | Year |
---|---|
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Other Studies
28 other studies available for candesartan and Cardiomegaly
Article | Year |
---|---|
Augmented sphingosine 1 phosphate receptor-1 signaling in cardiac fibroblasts induces cardiac hypertrophy and fibrosis through angiotensin II and interleukin-6.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compound | 2017 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; | 2016 |
Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice.
Topics: Age Factors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
Topics: Action Potentials; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atr | 2009 |
Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Benzi | 2010 |
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2010 |
Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors.
Topics: Adrenergic beta-Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrial Natr | 2010 |
[Drug therapies following heart failure and myocardial infarction(discussion)].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2002 |
Candesartan inhibits sinoaortic denervation-induced cardiovascular hypertrophy in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl | 2002 |
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2002 |
Down-regulation of bradykinin B2-receptor mRNA in the heart in pressure-overload cardiac hypertrophy in the rat.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Cardiom | 2003 |
Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; ARNTL Transcriptio | 2003 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2004 |
Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2004 |
Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2006 |
A novel mechanism of mechanical stress-induced hypertrophy.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Chlorocebus aethiops; COS Cells; Enzyme A | 2006 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardi | 1995 |
Effect of an AT1 receptor antagonist (CV-11974) on angiotensin II-induced cardiomyocyte hypertrophy in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blott | 1994 |
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy.
Topics: Animals; Animals, Newborn; Antibodies; Benzimidazoles; Biphenyl Compounds; Calcium-Calmodulin-Depend | 1996 |
Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardi | 1998 |
Role of cardiac nonmyocytes in cyclic mechanical stretch-induced myocyte hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compo | 1997 |
Role of ion channels and exchangers in mechanical stretch-induced cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Calcium-Calmodulin-Dependent Protein Ki | 1998 |
Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2002 |